10-Q
Quarterly Report
ADIAL PHARMACEUTICALS, INC.
ADIL
NASDAQ
CIK: 1513525
File #: 001-38323
Balance Sheet
28 line items · 2 periods
XBRL
| Item | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|
ASSETS | ||
Current Assets: | ||
Cash and cash equivalents | 5,025,110 | 2,827,082 |
Prepaid research and development | 36,000 | — |
Prepaid expenses and other current assets | 275,356 | 371,597 |
Total Current Assets | 5,336,466 | 3,198,679 |
Equity Method Investments | — | 456,191 |
Intangible assets, net | 3,772 | 3,913 |
Equity method investment | 1,344,143 | 1,534,013 |
Equity Method Investments | 1,344,143 | 1,534,013 |
Total Assets | 6,684,381 | 4,736,605 |
Current Liabilities: | ||
Accounts payable | 177,468 | 103,325 |
Accounts payable, related party | — | 24,062 |
Accrued expenses | 375,263 | 477,747 |
Accrued expenses, related party | 10,000 | 47,942 |
Total Current Liabilities | 562,731 | 653,076 |
Equity Method Investments | — | 631,940 |
Total Liabilities | 562,731 | 653,076 |
Stockholders’ Equity | ||
Common Stock, 50,000,000 shares authorized with a par value of $0.001 per share, 4,054,861 and 1,663,421 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 4,054 | 1,663 |
Additional paid in capital | 81,392,028 | 72,879,738 |
Accumulated deficit | (75,274,432) | (68,797,872) |
Total Stockholders’ Equity | 6,121,650 | 4,083,529 |
Common Stock | 4,054 | 1,663 |
Additional Paid In Capital | 81,392,028 | 72,879,738 |
Accumulated Deficit | (75,274,432) | (68,797,872) |
Total Liabilities and Stockholders’ Equity | 6,684,381 | 4,736,605 |